Neuro-ophthalmic Manifestations of Multiple System Atrophy

Multiple System Atrophy (MSA) is a rare brain disease. It damages parts of the brain that control movement, balance, and automatic body functions like blood pressure and bladder control. Doctors often group it into two forms: MSA-P (parkinsonism-predominant) and MSA-C (cerebellar-predominant). The damage can also affect eye control and eye reflexes, so some people develop visual problems even when standard eyesight (sharpness, color, and visual fields) is mostly normal. These eye problems come from brain and nerve pathways, not from the eyeball itself. EyeWiki

Multiple System Atrophy is a fast-moving, adult-onset brain disease that affects movement and the body’s automatic functions. It also affects the eyes and vision—mainly how the eyes move and blink—leading to symptoms like shaky vision (oscillopsia), nystagmus, eye movement inaccuracy, dry eye, and sometimes eyelid spasm or trouble opening the eyelids. These problems come from damage in the cerebellum and related pathways and from autonomic nervous system failure. There is no cure yet; care focuses on relieving symptoms and preventing complications. EyeWikiPMC

---

What “neuro-ophthalmic manifestations” means here

Neuro-ophthalmic” means eye problems caused by the brain and nerves rather than the eye itself. In MSA, typical eye findings include: impaired smooth pursuit (eye tracking), saccadic hypometria (short, undershooting eye jumps), excessive square-wave jerks (tiny unwanted saccades during fixation), gaze-evoked or downbeat nystagmus (eyes drift and jerk), reduced vestibulo-ocular reflex (eyes don’t hold fixation with head turns), dry eye from reduced blinking and autonomic dysfunction, blepharospasm (involuntary eyelid closure), and sometimes apraxia of eyelid opening (difficulty initiating lid opening). Visual acuity and color vision are usually preserved. Vertical gaze palsy is uncommon in MSA and should raise concern for PSP instead. EyeWiki

It means eye symptoms and signs caused by brain and nerve dysfunction in MSA. The common ones involve:

• Abnormal eye movements (difficulty keeping the eyes steady, tracking a moving target, or making quick jumps to a new target).

• Nystagmus (eyes “wiggle” or drift and jerk back).

• Saccadic problems (the quick eye jumps are too small or overshoot, or fixation is interrupted by little unwanted jumps called square-wave jerks).

• Vestibulo-ocular reflex (VOR) problems (the reflex that keeps vision steady when the head moves does not cancel or adapt normally).

• Pupil and eyelid problems (pupils may react abnormally due to autonomic failure; some people have eyelid spasms or difficulty opening the lids).
  These patterns are well described in clinical studies and reviews of MSA. EyeWikiPubMed+1nzbri.org

---

Types of neuro-ophthalmic problems seen in MSA

1) Fixation instability and saccadic intrusions
People may have frequent tiny unwanted eye jumps during steady fixation, called square-wave jerks. These can be very common in MSA and make it hard to keep a word or object clear. nzbri.orgFrontiers

2) Saccadic hypometria (undershooting)
When the eyes jump to a new target, the movement may be too short, so a second corrective jump is needed. This is typical in MSA and reflects basal ganglia and cerebellar involvement. nzbri.org

3) Impaired smooth pursuit
Following a moving object smoothly is often poor. The eyes make many small “catch-up” jumps to compensate. This is common in MSA and can help distinguish it from Parkinson’s disease in some testing setups. PMCneuroClues

4) Nystagmus (several patterns)
Gaze-evoked nystagmus and downbeat nystagmus can appear in MSA, especially in the cerebellar form. People may feel oscillopsia, which is the sense that the world is bouncing. EyeWikinzbri.org

5) Vestibulo-ocular reflex (VOR) and VOR-cancellation deficits
Most patients with MSA show impaired cancellation of the VOR (the brain cannot “turn off” the stabilizing reflex when tracking a target while the head moves). This points to cerebellar pathway dysfunction. PubMed

6) Pupillary autonomic dysfunction
Autonomic failure in MSA can affect pupil responses. Dynamic pupillometry studies show abnormal dilation/constriction dynamics in some patients, which can contribute to problems with glare, dim-light vision, and focusing changes. ScienceDirectPubMed

7) Eyelid disorders
Some people have blepharospasm (eyelid spasms) or apraxia of eyelid opening (trouble initiating lid opening). These disorders also occur in other movement disorders but are reported in MSA cohorts. EyeWikiPMC+1

8) Dry eye related to reduced blinking and autonomic changes
Blink rate can be reduced in parkinsonian disorders, and autonomic dysfunction can alter tear production, causing gritty, burning, or fluctuating vision. This is well described in related movement disorders and noted in MSA summaries. EyeWikiPMCFrontiers

9) Retinal structural changes on OCT (research finding)
Some studies show thinning of the retinal nerve fiber layer and macular layers in MSA on optical coherence tomography (OCT), even when the person does not notice vision loss. This is a research marker rather than a specific diagnostic test. PMC+1

10) Vision changes from orthostatic hypotension
A sudden drop in blood pressure on standing can cause transient blurred or blacked-out vision. This symptom is common in autonomic failure, including MSA. Mayo ClinicVanderbilt University Medical CenterPubMed

---

Causes

Each “cause” below is a driver or contributor inside the nervous system or body that explains why the eye problems happen in MSA.

1. Cerebellar degeneration impairs gaze-holding and smooth pursuit, causing gaze-evoked nystagmus and “bouncy” vision. EyeWiki

2. Basal ganglia dysfunction leads to undershooting saccades and frequent corrective jumps. nzbri.org

3. Defective VOR cancellation from cerebellar flocculus/paraflocculus damage prevents normal suppression of the head-movement reflex during tracking. PubMed

4. Neuronal loss in pontine and olivopontocerebellar pathways disrupts eye-movement circuits. EyeWiki

5. Square-wave jerks arise from cerebellar–brainstem control failure of fixation. nzbri.org

6. Downbeat nystagmus reflects floccular pathway dysfunction in the cerebellum. EyeWiki

7. Autonomic failure of the pupil blunts dilation in the dark and alters constriction in light, leading to night-vision and glare issues. ScienceDirect

8. Reduced blink rate in parkinsonian states destabilizes the tear film, causing dry eye and fluctuating clarity. Frontiers

9. Blepharospasm and eyelid opening apraxia come from basal ganglia network dysfunction affecting eyelid motor control. PMC

10. Brainstem “neural integrator” failure weakens gaze-holding, creating gaze-evoked nystagmus. nzbri.org

11. Impaired smooth pursuit generators in cerebellum/brainstem force the eyes to use catch-up saccades instead of true smooth tracking. PMC

12. Vestibular pathway involvement reduces VOR stability so the world blurs with head motion (oscillopsia). EyeWiki

13. Orthostatic hypotension lowers blood flow to the visual brain and retina during standing, causing transient blur or “grey-out.” PubMed

14. Dry eye from autonomic changes reduces tear production and increases evaporation, worsening visual fluctuation. PMC

15. Abnormal blink reflex circuits (brainstem) change protective eye reflexes and comfort. EyeWiki

16. Retinal layer thinning on OCT reflects neurodegeneration that may subtly affect contrast and stability over time. PMC

17. Putaminal and pontocerebellar atrophy on MRI signal the structural network injury that underlies many oculomotor signs. PMC

18. Misfolded alpha-synuclein in glial cells (glial cytoplasmic inclusions) is the disease hallmark and drives widespread circuitry failure, including eye pathways. EyeWiki

19. Poor VOR–pursuit interaction during combined head–eye tracking tasks contributes to reading and motion-sensitivity complaints. PubMed

20. Medication sensitivity in MSA (e.g., limited levodopa response with autonomic side effects) can amplify dry eye or focusing complaints in some patients, even when not the primary cause. (This is a clinical inference grounded in MSA management patterns.) EyeWiki

---

Common symptoms

1. Blurry vision that comes and goes (often worse with motion or fatigue). This often reflects poor pursuit or tear-film instability. EyeWiki

2. Double vision at times, especially when tired or during quick head turns, due to unstable eye movements rather than fixed misalignment. Mayo Clinic

3. Oscillopsia (the world looks like it is bouncing) during walking or head turns, from VOR problems or nystagmus. EyeWiki

4. Trouble tracking a moving object (sports, traffic, scrolling text), because smooth pursuit is impaired. PMC

5. Needing extra small eye jumps to land on a word or target, due to saccadic hypometria. nzbri.org

6. Frequent “micro-jumps” of the eyes at rest, which disturb reading lines (square-wave jerks). nzbri.org

7. Light sensitivity or glare from pupil dysfunction and dry eye. ScienceDirect

8. Night-vision difficulty because pupils may not dilate well and fixation is unstable. ScienceDirect

9. Eye burning, grittiness, or fluctuating vision from dry eye due to reduced blinking and autonomic changes. PMC

10. Eyelid spasms that squeeze the eyes shut (blepharospasm). EyeWiki

11. Trouble getting the eyelids to open after a blink (apraxia of eyelid opening) in a subset of patients. PMC

12. Brief “blackout” or greying of vision when standing up, from orthostatic hypotension. PubMed

13. Reading fatigue because fixation is unstable and tracking is inefficient. nzbri.org

14. Motion sensitivity in busy visual environments due to impaired integration of head and eye cues. PubMed

15. Dry, sore eyelids from reduced blink and meibomian changes associated with parkinsonian states. Frontiers

Note: In MSA, standard visual acuity, color vision, and visual fields are often normal or near normal, which helps doctors separate these complaints from optic nerve disease. EyeWiki

---

Diagnostic tests

Below are 20 tests, grouped into Physical Exam, Manual (bedside) maneuvers, Lab/Pathology, Electrodiagnostic, and Imaging. Each entry explains what the test looks for in plain terms.

A) Physical Exam (bedside observation with minimal tools)

1. Fixation and square-wave jerk check
   The clinician asks you to look at a dot and watches for tiny back-and-forth jumps. Frequent square-wave jerks suggest cerebellar or basal ganglia problems seen in MSA. nzbri.org

2. Saccade testing (look quickly between two targets)
   The examiner checks if eye jumps undershoot and need corrections. Frequent undershoot fits MSA patterns. nzbri.org

3. Smooth pursuit testing (follow a slow moving target)
   If your eyes cannot follow smoothly and use many catch-up jumps, this supports cerebellar involvement common in MSA. PMC

4. Gaze-holding and nystagmus check
   Looking to the side or down may bring out nystagmus, including downbeat or gaze-evoked types, which fit MSA-C. EyeWiki

B) Manual tests (simple, hands-on maneuvers)

5. Head impulse and VOR-cancellation tests
   The clinician gently moves your head while you fixate on a target, and then tests tracking a target while head and target move together. In MSA, VOR cancellation is often abnormal. PubMed

6. Optokinetic nystagmus (OKN) strip or drum
   Watching moving stripes should trigger a regular tracking nystagmus. An abnormal response supports central pathway dysfunction. (Often abnormal in degenerative cerebellar disorders including MSA.) PMC

7. Pupil light and near response
   Light and near-focus reactions can be sluggish or symmetric but abnormal in timing in MSA due to autonomic failure. ScienceDirect

8. Blink rate and eyelid function exam
   The clinician counts blinks and looks for blepharospasm or difficulty initiating eyelid opening. These problems are reported in MSA cohorts. EyeWikiPMC

C) Lab and Pathology (to support diagnosis or rule out mimics)

9. Autonomic blood tests and rule-out labs
   No blood test confirms MSA, but labs help exclude other causes of dysautonomia or visual complaints (e.g., diabetes, thyroid issues, vitamin B12 deficiency, infections or autoimmune disease). This is routine in workups of autonomic and neuro-ophthalmic complaints. EyeWiki

10. Medication review and targeted labs
    Doctors review drugs that worsen orthostatic symptoms or dry eye (e.g., antihypertensives, anticholinergics) and order labs as needed to check for side effects or mimics.

11. Urine/urodynamic studies (part of autonomic domain)
    Though not an eye test, documentation of autonomic failure supports the MSA diagnosis when eye signs are subtle. EyeWiki

12. Pathology (post-mortem confirmation only)
    Definite MSA needs pathology showing alpha-synuclein in glial cells. This is not a clinical test but explains why living diagnosis relies on patterns across systems. EyeWiki

D) Electrodiagnostic and instrumented oculomotor tests

13. Video-oculography (VOG) or electro-oculography (EOG)
    These tools record eye position to measure square-wave jerks, saccade size and speed, pursuit gain, and nystagmus precisely. They often show the classic MSA pattern (frequent SWJ, hypometric saccades, poor pursuit). nzbri.org

14. Dynamic pupillometry (infrared pupillography)
    This measures how fast and how much the pupils react to light and darkness. In MSA, dynamics can be abnormal and may track disease severity. ScienceDirect

15. Blink reflex testing (EMG of orbicularis oculi)
    Surface electrodes assess brainstem reflex circuits that control protective blinking; abnormalities support central pathway involvement in parkinsonian syndromes.

16. Visual evoked potentials (VEP)
    VEP checks the optic pathway to the brain. It is often normal in MSA but helps rule out optic nerve disease when vision complaints exist for other reasons.

E) Imaging tests

17. Brain MRI
    MRI may show atrophy of the pons, cerebellum, or putamen. In some MSA-C patients, a “hot cross bun” sign appears in the pons. This sign supports, but does not by itself prove, the diagnosis. PMC+1Radiopaedia

18. Advanced MRI markers
    Diffusion measures and other quantitative MRI techniques can strengthen diagnostic confidence and track progression in research and specialty centers. SpringerLink

19. Optical Coherence Tomography (OCT)
    OCT can show thinning of retinal nerve fiber and macular layers in some MSA patients. It is noninvasive and useful as a supportive biomarker, not a primary diagnostic test. PMC+1

20. Autonomic testing with tilt-table (physiology + monitoring)
    This is not an eye test, but it documents orthostatic hypotension, which explains visual blackouts and supports the MSA diagnosis when combined with eye signs. Penn Medicine

Non-pharmacological treatments

Below are evidence-based, low-risk strategies. For each item you’ll see what it is, why, and how it helps.

1. Slow, staged position changes
   Description: Sit up in bed, pause, dangle legs, stand slowly.
   Purpose: Reduce lightheadedness and vision dimming from nOH.
   Mechanism: Gives blood pressure time to adjust. PMC

2. Hydration routine
   Description: Regular fluids across the day; consider a 300–500 mL water bolus before standing or activity if your clinician approves.
   Purpose: Improves circulating volume and BP stability.
   Mechanism: Water bolus triggers a brief sympathetic response that raises BP in nOH. PMC

3. Salt liberalization (if your doctor says it’s safe)
   Description: More dietary salt or electrolyte drinks when not contraindicated.
   Purpose/Mechanism: Expands plasma volume to support BP and brain/retinal perfusion. PMC

4. Compression garments
   Description: Waist-high compression stockings and/or an abdominal binder during daytime.
   Purpose: Prevents blood pooling in legs/abdomen.
   Mechanism: Mechanical venous return support, stabilizing standing BP and vision. PMC

5. Head-of-bed elevation
   Description: Sleep with the head of the bed up 10–20 degrees.
   Purpose: Less nighttime diuresis and morning nOH.
   Mechanism: Reduces kidney-driven volume loss overnight. PMC

6. Small, lower-carb meals
   Description: Eat modest meals; avoid heavy, high-carb lunches.
   Purpose: Reduces post-meal BP drops and after-meal blurred vision.
   Mechanism: Limits splanchnic vasodilation/postprandial hypotension. PMC

7. Physical counter-maneuvers
   Description: Leg crossing, calf tensing, buttock clenching before standing or when dizzy.
   Purpose/Mechanism: Raises BP temporarily by boosting venous return. PMC

8. Recumbent or water-based exercise
   Description: Recumbent cycling, rowing, or pool-based exercise.
   Purpose: Maintain fitness without big BP drops.
   Mechanism: Exercise in positions that minimize orthostatic stress. PMC

9. Blink training & scheduled blinking
   Description: Reminders to blink fully, especially at screens.
   Purpose: Reduce dry eye and ocular surface damage.
   Mechanism: Restores tear film stability by normalizing blink mechanics. PMC

10. Lid hygiene + warm compresses
    Description: Daily warm compresses and gentle lid scrubs.
    Purpose: Treat meibomian gland dysfunction contributing to dry eye.
    Mechanism: Improves oil flow, slows tear evaporation. AAO Journal

11. Humidify and adjust the environment
    Description: Humidifiers, avoid direct fans/AC to eyes, take screen breaks.
    Purpose/Mechanism: Reduces tear film evaporation and surface stress. AAO Journal

12. Moisture-chamber glasses / wraparound eyewear
    Description: Goggle-style eyewear outdoors and in dry rooms.
    Purpose: Keeps tears from evaporating; protects from wind and dust.
    Mechanism: Creates a humid micro-environment over the cornea. AAO Journal

13. Tinted lenses for photophobia / oscillopsia comfort
    Description: FL-41 or other tints as tolerated.
    Purpose: Reduce light sensitivity and visual discomfort.
    Mechanism: Filters irritating wavelengths; may lessen perceived flicker. PMC

14. Eyelid crutches (on eyeglass frames) for AEO
    Description: A small shelf attached to glasses to hold lids up.
    Purpose: Non-surgical help for eyelid opening difficulty.
    Mechanism: Mechanical lift of the upper lid. ScienceDirect

15. Intermittent patching for bothersome diplopia
    Description: Short periods of occluding one eye if brief double vision occurs.
    Purpose: Stops double images when prisms aren’t helpful.
    Mechanism: Eliminates binocular conflict (use sparingly). PubMed

16. Low-vision aids when oscillopsia is severe
    Description: Large-print devices, high-contrast settings, e-readers, audio books.
    Purpose: Maintain reading and work independence.
    Mechanism: Compensates for unstable fixation. PubMed

17. Occupational therapy home safety plan
    Description: Brighter lighting, contrast tape on steps, clear floor paths.
    Purpose: Reduce falls when vision is shaky.
    Mechanism: Improves environmental cues and footing. EyeWiki

18. Sleep hygiene for REM behavior disorder (common in MSA)
    Description: Safe bedroom setup, remove hazards; discuss melatonin with clinician.
    Purpose: Prevent nighttime injuries that can affect eyes/face.
    Mechanism: Risk reduction around parasomnia. PMC

19. Avoid alcohol and sedatives if possible
    Description: Limit substances that worsen balance and pursuit.
    Purpose/Mechanism: Alcohol and sedatives aggravate cerebellar eye instability. Frontiers

20. Regular neuro-ophthalmology follow-up
    Description: Baseline exam and periodic checks.
    Purpose: Track nystagmus, eyelid function, dryness; update treatment.
    Mechanism: Early detection of changes improves symptom control. PubMed

---

Drug treatments

*Always individualize with your doctor—doses below reflect common study/label ranges.

1. Midodrine (α-1 agonist)
   Dose/Timing: Start 2.5–5 mg three times daily while upright; avoid within 4 h of bedtime.
   Purpose: Treats nOH to reduce vision “graying out” and falls.
   Mechanism: Peripheral vasoconstriction raises standing BP.
   Side effects: Scalp tingling, gooseflesh, urinary retention, supine hypertension. JWatchPubMed

2. Droxidopa (norepinephrine pro-drug)
   Dose/Timing: Start 100 mg three times daily, titrate every 24–48 h up to 600 mg TID as needed; avoid near bedtime.
   Purpose/Mechanism: Increases endogenous NE to lift standing BP in nOH.
   Side effects: Headache, hypertension (including supine), nausea. PubMed

3. Fludrocortisone (mineralocorticoid)
   Dose: Often 0.1 mg daily (some patients need 0.2 mg); monitor potassium and edema.
   Purpose/Mechanism: Expands plasma volume and sensitizes vasculature.
   Side effects: Edema, hypokalemia, supine hypertension, heart failure risk in susceptible patients. PMC

4. Pyridostigmine (acetylcholinesterase inhibitor)
   Dose: Commonly 30–60 mg up to 3×/day while upright.
   Purpose: Adjunct for nOH—often improves standing BP without worsening supine BP.
   Mechanism: Enhances ganglionic transmission when upright.
   Side effects: GI cramps, diarrhea, sweating, urinary urgency. PubMedJAMA Network

5. Octreotide (somatostatin analog)
   Dose: 25–50 µg subcutaneously 30–60 min before large meals (for severe post-prandial hypotension).
   Purpose/Mechanism: Reduces splanchnic vasodilation after meals to stabilize BP and vision.
   Side effects: Abdominal pain, gallstones, hyperglycemia; monitor. PMCPubMed

6. OnabotulinumtoxinA / IncobotulinumtoxinA (botulinum toxin A)
   Use: First-line for blepharospasm and sometimes AEO (levator injections in AEO).
   Dose/Timing: Injected by trained specialists every ~3 months; dose varies by pattern.
   Purpose/Mechanism: Temporarily weakens overactive eyelid muscles to relieve forced closure or opening failure.
   Side effects: Temporary ptosis, dry eye, bruising; rare diplopia. PubMedScienceDirect

7. 4-Aminopyridine / Dalfampridine (potassium channel blocker)
   Dose (trial examples): 4-AP 5–10 mg QID or sustained-release 10 mg BID (off-label for nystagmus; seizure risk screening needed).
   Purpose: Reduce downbeat/gaze-evoked nystagmus and oscillopsia in cerebellar disease (including MSA-C).
   Mechanism: Enhances Purkinje cell output to stabilize gaze.
   Side effects: Paresthesias, dizziness, seizure risk at higher levels or predisposition. PubMed+1PMC

8. Baclofen (GABA-B agonist)
   Dose: Often 5–10 mg TID, titrate; used when periodic alternating nystagmus is present.
   Purpose/Mechanism: Dampens central oscillators generating PAN.
   Side effects: Sedation, dizziness, weakness; taper if discontinuing. PMC

9. Gabapentin or Memantine
   Dose: Gabapentin 900–1200 mg/day divided; Memantine 10–20 mg/day.
   Purpose: Off-label for acquired pendular nystagmus and oscillopsia (more data in MS; occasionally used symptomatically in cerebellar disease).
   Mechanism: Reduces central oscillation gain.
   Side effects: Drowsiness (gabapentin), confusion/headache (memantine). PMC

10. Cyclosporine 0.05–0.1% or Lifitegrast 5% (topical anti-inflammatories for dry eye)
    Dose: One drop twice daily to each eye; onset is weeks.
    Purpose/Mechanism: Calms ocular surface inflammation to improve tear film in chronic dry eye that persists despite lubrication.
    Side effects: Stinging on instillation, transient blur; lifitegrast can leave a taste. ScienceDirectNutraceutical Business Review

---

Dietary “molecular” supplements

Important: No supplement has proven disease-modifying benefit in MSA. Use only to correct deficiencies or for comfort, and discuss with your clinician to avoid interactions.

1. Vitamin D3 (e.g., 1000–2000 IU/day; higher only if deficient) — supports neuromuscular function; deficiency links to dry-eye and general frailty.

2. Vitamin B12 (dose depends on level) — correct deficiency to support nerve function and reduce fatigue; deficiency can worsen neurologic symptoms. PMC

3. Omega-3 fatty acids (EPA/DHA) (~1 g/day from food or capsules) — may help ocular surface comfort, though a large randomized trial (DREAM) found no advantage over placebo; favor dietary fish. PMC

4. Magnesium (200–400 mg elemental/day if low) — helps muscle cramps and sleep; monitor in kidney disease. PMC

5. Lutein + Zeaxanthin (e.g., 10 mg/2 mg daily) — macular pigment support for overall retinal resilience; not MSA-specific. PMC

6. Coenzyme Q10 (100–300 mg/day) — widely used; no clear benefit in synucleinopathies but generally well tolerated. Diabetes Journals

7. Alpha-lipoic acid (300–600 mg/day) — neuropathic symptom support in other conditions; evidence in MSA is limited. JAMA Network

8. Taurine (500–1000 mg/day) — experimental retinal support; clinical data limited. PMC

9. Curcumin (up to 500–1000 mg/day) — anti-inflammatory properties; avoid with anticoagulants; evidence in MSA is lacking. PMC

10. Electrolyte solutions (as needed) — practical aid for hydration and nOH on hot days or during illness. PMC

---

Regenerative / stem-cell / immune” therapies

Bottom line: There are no approved immune boosters or regenerative/stem-cell drugs for MSA. Several investigational approaches are in trials; none is standard of care today. If you are interested, discuss clinical trial enrollment—that’s the safe, ethical path.

1. Mesenchymal stem cells (MSC; IV or intra-arterial) — small trials in MSA suggest possible slowing, but evidence is preliminary and mixed; safety and durability remain under study. Not approved for routine use. ClinicalTrials.gov+1

2. Anti-α-synuclein antibodies (e.g., TAK-341, Lu AF82422) — aim to clear toxic α-syn species; phase 2/3 programs ongoing; not yet proven effective. PubMedHealth Research AuthorityNeurology live

3. MPO inhibitors (verdiperstat/BHV-3241) — failed its phase 3 MSA trial; not recommended. Neurology live

4. Iron chelation / metal-targeting (ATH434/“PBT434”) — phase 2 data (2025) reported slowed progression in early MSA; needs confirmatory trials before clinical use. Alterity TherapeuticsCND Life Sciences

5. Erythropoietin (EPO) — niche use in MSA patients with documented EPO-deficiency anemia and severe nOH; case series suggest improved BP/anemia, but this is not a disease-modifier and requires careful hematology oversight. PubMed+1

6. Gene/oligonucleotide strategies — conceptual and preclinical; not available clinically for MSA at this time. ScienceDirect

---

Procedures/surgeries

1. Botulinum toxin injections (office procedure)
   Why: First-line for blepharospasm; sometimes helpful in AEO.
   How: Precisely placed injections weaken overactive eyelid muscles for ~3 months. PubMed

2. Frontalis suspension (frontalis sling) for refractory AEO
   Why: When severe eyelid opening failure persists despite botulinum therapy.
   How: A sling links the eyelid to the forehead muscle to assist opening; many series report meaningful, durable benefit in selected patients. PMCPubMed

3. Orbicularis oculi myectomy (limited or radical) for refractory blepharospasm
   Why: Reduces the power of spasm-producing muscles when injections fail or wear off too quickly.
   How: Surgical removal/weakening of segments of the eyelid protractor muscles; modern series show improved function and quality of life for most candidates. E-JMDPubMed

4. Punctal occlusion (plugs or cautery) for severe dry eye
   Why: When maximal drops/ointments and lid care are not enough.
   How: Blocks tear drainage to conserve natural tears; improves symptoms and ocular surface in many patients. PMCAAO Journal

5. Rare strabismus surgery (select cases)
   Why: If a stable, bothersome ocular misalignment persists and prism or patching fails.
   How: Small adjustments to eye muscles to reduce double vision; candidacy is uncommon in MSA and must be individualized. PubMed

---

Prevention tips

1. Treat nOH early (behavioral steps + meds if needed) to prevent blackouts and vision “gray-outs.” PMC

2. Protect the ocular surface every day (blink breaks, warm compresses, humidify). AAO Journal

3. Sun/wind protection with wraparound eyewear outdoors. AAO Journal

4. Fall-proof your home with brighter lights and clear paths. EyeWiki

5. Schedule eye checks with a neuro-ophthalmologist to track nystagmus/eyelids. PubMed

6. Manage meds that worsen hypotension (e.g., some BP pills), with your doctor. PMC

7. Prefer small, lower-carb meals to prevent postprandial dips. PMC

8. Avoid alcohol and overheating (saunas, hot tubs) that drop BP. PMC

9. Keep vaccinations current (flu, COVID-19, pneumococcal) to avoid illnesses that can dangerously dehydrate you and worsen nOH. PMC

10. Ask about driving safety if you have oscillopsia or unpredictable blackouts. EyeWiki

---

When to see a doctor urgently

• New, constant double vision;

• Sudden vision loss or a dark curtain over vision;

• Painful red eye (risk of corneal abrasion from severe dry eye);

• Frequent fainting or head injuries;

• Worsening eyelid spasms that shut your eyes;

• Medication side effects like severe supine hypertension (headache at night, nosebleeds).
  These are red flags that need prompt assessment. EyeWikiPMC

---

What to eat and what to avoid

Eat more of:

1. Fluids + electrolytes across the day (unless restricted). Helps nOH. PMC

2. Adequate salt (only if your clinician okays it). Supports volume. PMC

3. Lean proteins and high-fiber vegetables with meals. Blunts post-meal dips. PMC

4. Oily fish (salmon, sardines) 2–3×/week for omega-3s and general eye comfort. PMC

5. Vitamin-D–rich foods (eggs, fortified dairy) and test-guided supplementation.

Limit or avoid:

1. Large, high-carb meals (white rice, sweets) that trigger postprandial hypotension. PMC
2. Alcohol, which worsens balance, pursuit, and BP control. PMC
3. Very hot drinks/meals in large portions (can magnify vasodilation). PMC
4. Dehydration triggers: long heat exposure without fluids; plan “drink breaks.” PMC
5. Miracle” supplements promising MSA cures—none are proven; prioritize trial-backed care. PMC

---

FAQs

1) Is vertical gaze palsy typical of MSA?
No. It’s much more typical of progressive supranuclear palsy (PSP). In MSA, tracking and saccadic undershoot plus nystagmus are more characteristic. EyeWiki

2) Why does my vision shake when I walk?
That’s oscillopsia from nystagmus and a weak vestibulo-ocular reflex (the gaze-stabilizing reflex). EyeWiki

3) Can glasses fix oscillopsia?
Glasses correct refractive blur, not eye-movement oscillation. Tints and moisture-chamber frames can aid comfort; medicines like 4-AP may help certain nystagmus types. PubMed

4) Are dry eyes part of MSA?
Very often, due to reduced blinking and autonomic issues. Lid hygiene, humidification, and anti-inflammatory drops can help. EyeWiki

5) What is apraxia of eyelid opening?
A problem initiating eyelid lift. Botulinum injections (including into the levator in selected cases) and, rarely, frontalis sling surgery can help. ScienceDirectPMC

6) Will botulinum toxin make my eyes too weak?
Doses are titrated to reduce spasm while preserving function. Temporary droop or dryness can occur and usually settles. PubMed

7) Why do I gray out when I stand?
Neurogenic orthostatic hypotension drops blood pressure quickly, reducing blood flow to the brain and eyes. Treating nOH often improves visual symptoms. AHA Journals

8) Which nOH medicine is “best”?
Midodrine and droxidopa are most used; fludrocortisone and pyridostigmine are add-ons. The “best” is the one that raises your standing BP without causing dangerous supine hypertension—your team will tailor it. JWatchPubMed

9) Does atomoxetine help nOH?
Earlier small studies suggested benefit; a recent randomized trial did not beat placebo for symptom relief, so it’s not routine. PMC

10) Can 4-aminopyridine stop my nystagmus?
It can reduce downbeat/gaze-evoked nystagmus in some patients and improve function, but it’s off-label and not for everyone (screening for seizure risk is essential). PubMed

11) Do supplements slow MSA?
No proven supplements change MSA’s course. Use them to correct deficiencies or for comfort after discussing with your clinician. PMC

12) Are stem cells a cure yet?
No. Stem-cell approaches are experimental. Consider clinical trials if interested; avoid pay-to-participate “clinics.” ClinicalTrials.gov

13) Is surgery common for eye problems in MSA?
Not common. Most patients do well with injections, drops, and lifestyle changes. Surgery is reserved for carefully selected, refractory cases. PMCE-JMD

14) How often should I see an eye specialist?
At diagnosis for a baseline, then periodically (often yearly, more often if symptomatic) to adjust treatment. PubMed

15) What’s the overall outlook?
MSA is progressive. Early, proactive symptom management—especially for nOH and ocular surface health—can meaningfully improve daily comfort and safety. PMC

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: August 14, 2025.